Bill 118 HR 3329, also known as the End Taxpayer Funding of Gender Experimentation Act of 2023, aims to prohibit the use of federal funds for gender reassignment surgeries and treatments. The bill specifically targets taxpayer dollars that would be used to cover these procedures for individuals seeking to transition from one gender to another.
Supporters of the bill argue that taxpayer money should not be used to fund what they refer to as "gender experimentation," and that individuals should be responsible for covering the costs of these procedures themselves. They also argue that there are more pressing healthcare needs that should be prioritized with federal funds.
Opponents of the bill argue that denying coverage for gender reassignment procedures is discriminatory and goes against the rights of transgender individuals. They argue that these procedures are medically necessary for some individuals and should be covered by insurance, including federal programs.
The bill has sparked debate among lawmakers and advocacy groups, with both sides presenting strong arguments for and against its passage. As of now, the bill is still in the early stages of the legislative process and its ultimate fate remains uncertain.